# BPC-157 TB-500 FAQ: the Wolverine blend, answered from the literature

> BPC-157 TB-500 FAQ — the Wolverine blend answered from the published record: what the two peptides are, how they differ, the synergy and safety questions, dosing context, and the FDA 503A and WADA status. Cited to source.

Twenty-five questions on the Wolverine blend — definitional, mechanistic, safety, dosing, and regulatory — each answered directly and cited where the claim is quantitative.

## Identity and definitions

The first set of BPC-157 TB-500 questions is definitional: what the blend is, what each constituent is, and how the two differ.

## Mechanism and evidence

These questions cover how each peptide works, whether they act through the same pathway, and what the combination evidence actually shows.

## Safety questions

The safety questions are answered honestly against a thin record: there is no controlled human safety dataset for the blend, and one preclinical signal — tumor angiogenesis — is worth naming.

## Dosing, half-life, and handling

These answers are research-context only. They report study parameters and handling practice, never human dosing guidance. Full detail sits on [BPC-157 TB-500 dosage in the research literature](/dosage).

## Regulatory and access

The regulatory answers reflect the present-tense FDA record. Full context, cited to FDA, is on [Wolverine legal status and FDA 503A compounding access](/legal-status).

---

Two constituent channels read off one console — BPC-157 traced to its studies and TB-500 to its own, the repair-signal node where they converge left dark because no combination trial exists, and the FDA 503A and WADA marks posted before anything else; no clinic behind the readout and nothing here dispensed.